BridgeMD
A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
EU CTIS ID: 2022-502833-25-00
What this study is testing
To demonstrate that Orforglipron is non-inferior to insulin glargine (with a non-inferiority margin of 1.8) in occurrence of MACE-4 events
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- have Type 2 Diabetes
- Be taking a consistent dose of 1 to 3 diabetes drugs by mouth for the last 3 months
- Have heart disease
- Have high blood sugar as measured by hemoglobin A1C (HbA1c at least 7.0%)
You likely can't join if
- Have type 1 diabetes
- Have history of inflamed liver (hepatitis)
- Have used any weight loss drugs, including herbal or nutritional supplements, within the last 3 month
- Have history of pancreatitis
The study team makes the final eligibility decision.
Where it's taking place
- Argentina
- Brazil
- Korea, Republic of
- Turkey
- United States
- India
- Mexico
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Argentina; Brazil; Korea, Republic of; Turkey; United States; India and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.